- Home
- TASK vs SANA Comparison
TASK vs SANA Comparison
Compare TASK & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- SANA
- Stock Information
- Founded
- TASK 2008
- SANA 2018
- Country
- TASK United States
- SANA United States
- Employees
- TASK N/A
- SANA N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- SANA Medicinal Chemicals and Botanical Products
- Sector
- TASK Technology
- SANA Health Care
- Exchange
- TASK Nasdaq
- SANA Nasdaq
- Market Cap
- TASK 1.1B
- SANA 983.4M
- IPO Year
- TASK 2021
- SANA 2021
- Fundamental
- Price
- TASK $13.04
- SANA $4.06
- Analyst Decision
- TASK Buy
- SANA Strong Buy
- Analyst Count
- TASK 4
- SANA 7
- Target Price
- TASK $17.25
- SANA $7.83
- AVG Volume (30 Days)
- TASK 481.6K
- SANA 6.8M
- Earning Date
- TASK 11-07-2025
- SANA 11-06-2025
- Dividend Yield
- TASK N/A
- SANA N/A
- EPS Growth
- TASK 48.21
- SANA N/A
- EPS
- TASK 0.88
- SANA N/A
- Revenue
- TASK $1,144,833,000.00
- SANA N/A
- Revenue This Year
- TASK $20.00
- SANA N/A
- Revenue Next Year
- TASK $11.47
- SANA N/A
- P/E Ratio
- TASK $14.83
- SANA N/A
- Revenue Growth
- TASK 19.88
- SANA N/A
- 52 Week Low
- TASK $11.26
- SANA $1.26
- 52 Week High
- TASK $19.60
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- TASK 36.69
- SANA 41.41
- Support Level
- TASK $12.41
- SANA $5.12
- Resistance Level
- TASK $14.36
- SANA $5.00
- Average True Range (ATR)
- TASK 0.48
- SANA 0.41
- MACD
- TASK 0.04
- SANA -0.22
- Stochastic Oscillator
- TASK 31.36
- SANA 19.33
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.